CoChat

COVID ‐19 Vaccine Response in People with Multiple Sclerosis

Open access
Tallantyre, Emma C., Vickaryous, Nicola, Anderson, Valerie, Asardag, Aliye Nazli, Baker, David, Bestwick, Jonathan, Bramhall, Kath, Chance, Randy, Evangelou, Nikos, George, Katila, Giovannoni, Gavin, Godkin, Andrew, Grant, Leanne, Harding, Katharine E., Hibbert, Aimee, Ingram, Gillian, Jones, Meleri, Kang, Angray S., Loveless, Samantha, Moat, Stuart J., Robertson, Neil P., Schmierer, Klaus, Scurr, Martin J., Shah, Sita Navin, Simmons, Jessica, Upcott, Mae, Willis, Mark, Jolles, Stephen, Dobson, Ruth · 2022 · Annals of Neurology
Cited by 158

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Objective: The purpose of this study was to investigate the effect of disease modifying therapies on immune response to severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) vaccines in people with multiple sclerosis (MS). Methods: Four hundred seventy‐three people with MS provided one or more dried blood spot samples. Information about coronavirus disease 2019 (COVID‐19) and vaccine history, medical, and drug history were extracted from questionnaires and medical records. Dried blood spots were eluted and tested for antibodies to SARS‐CoV‐2. Antibody titers were partitioned into tertiles with people on no disease modifying therapy as a reference. We calculated the odds ratio of seroconversion (univariate logistic regression) and compared quantitative vaccine response (Kruskal Wallis) following the SARS‐CoV‐2 vaccine according to disease modifying therapy. We used regression modeling to explore the effect of vaccine timing, treatment duration, age, vaccine type, and lymphocyte count on vaccine response. Results: Compared to no disease modifying therapy, the use of anti‐CD20 monoclonal antibodies (odds ratio = 0.03, 95% confidence interval [CI] = 0.01–0.06, p < 0.001) and fingolimod (odds ratio = 0.04; 95% CI = 0.01–0.12) were associated with lower seroconversion following the SARS‐CoV‐2 vaccine. All other drugs did not differ significantly from the untreated cohort. Both time since last anti‐CD20 treatment and total time on treatment were significantly associated with the response to the vaccination. The vaccine type significantly predicted seroconversion, but not in those on anti‐CD20 medications. Preliminary data on cellular T‐cell immunity showed 40% of seronegative subjects had measurable anti‐SARS‐CoV‐2 T cell responses. Interpretation: Some disease modifying therapies convey risk of attenuated serological response to SARS‐CoV‐2 vaccination in people with MS. We provide recommendations for the practical management of this patient group. ANN NEUROL 20219999:n/a–n/a

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ana.26251

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 158

Metadata

Authors
Tallantyre, E. C., Vickaryous, N., Anderson, V., Asardag, A. N., Baker, D., Bestwick, J., Bramhall, K., Chance, R., Evangelou, N., George, K., Giovannoni, G., Godkin, A., Grant, L., Harding, K. E., Hibbert, A., Ingram, G., Jones, M., Kang, A. S., Loveless, S., Moat, S. J., Robertson, N. P., Schmierer, K., Scurr, M. J., Shah, S. N., Simmons, J., Upcott, M., Willis, M., Jolles, S., & Dobson, R.
Venue
Annals of Neurology
Publisher
Wiley
Published
2021-11-17
Volume
91
Issue
1
Pages
89-100
ISSN
  • 0364-5134 (ISSN-L)
  • 1531-8249
OpenAlex
W3206641838
Cited by
158
References
15
FWCI
21.06
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: COVID ‐19 Vaccine Response in People with Multiple Sclerosis. https://app.cochat.ai/papers/10.1002/ana.26251
The paper
Tallantyre, E. C., Vickaryous, N., Anderson, V., Asardag, A. N., Baker, D., Bestwick, J., Bramhall, K., Chance, R., Evangelou, N., George, K., Giovannoni, G., Godkin, A., Grant, L., Harding, K. E., Hibbert, A., Ingram, G., Jones, M., Kang, A. S., Loveless, S., . . . Dobson, R. (2022). COVID ‐19 Vaccine Response in People with Multiple Sclerosis. Annals of Neurology. https://doi.org/10.1002/ana.26251

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.